Guide
Tirzepatide and PCOS: A Promising Signal With Thin Evidence
PCOS involves insulin resistance, and GLP-1s improve it, so the rationale is coherent. But no GLP-1 is approved for PCOS, the dedicated trial evidence is thin, and there
PCOS involves insulin resistance, and GLP-1s improve it, so the rationale is coherent. But no GLP-1 is approved for PCOS, the dedicated trial evidence is thin, and there is a specific fertility consideration: weight loss can restore ovulation, which changes contraception needs.
What is the rationale, and what is the evidence?
| Claim | Status |
|---|---|
| Insulin resistance is central to PCOS | Well established |
| GLP-1s improve insulin sensitivity | Well established |
| Weight loss improves PCOS symptoms | Well established, independent of method |
| A GLP-1 is approved for PCOS | No |
| Large dedicated PCOS trials exist | Thin. Mostly small studies and secondary analyses |
Weight loss can restore ovulation in people who were not ovulating. For someone trying to conceive that is a benefit. For someone not trying to conceive it is a contraception question that arrives without warning.
Separately, GLP-1s are not recommended in pregnancy, and labelling advises discontinuing before a planned pregnancy with a specified interval. If pregnancy is possible, that conversation belongs at the start of treatment rather than after.
Which molecule, if any?
The PCOS-specific comparative evidence between tirzepatide and semaglutide does not exist at the quality needed to answer that. What exists is general weight-loss superiority for tirzepatide (20.2% against 13.7% in SURMOUNT-5) and a completed cardiovascular outcomes trial for semaglutide. Neither addresses PCOS endpoints directly.
What about metformin, which most PCOS patients are already on?
Metformin is long-established in PCOS and works on insulin resistance through a different mechanism. Combination use is common in practice, and it is a prescriber's decision rather than an additive one a patient makes — gastrointestinal effects overlap heavily between the two, which is the practical constraint.
If you are already on metformin, say so at the intake. A telehealth programme that does not ask what else you take is not conducting the assessment it claims to.
Does insurance treat PCOS differently?
Usually badly. Without a type 2 diabetes or obesity code, coverage for a GLP-1 in PCOS is commonly denied, because no GLP-1 carries a PCOS indication. That places most PCOS patients on the cash routes, where the comparison is $186 flat for the cheapest captured compounded programme against $299 to $449 for brand vials.
It also means the cost question is a maintenance question. PCOS is chronic, the insulin resistance returns when treatment stops, and an entry price that escalates by dose is a poor structure for an indefinite condition.
| Trial | Population | Result | Duration |
|---|---|---|---|
| SURMOUNT-1 | Obesity or overweight, no diabetes | 22.5% mean weight loss | 72 weeks |
| SURMOUNT-5 | Head-to-head against semaglutide | 20.2% vs 13.7% | 72 weeks |
| SURPASS-2 | Type 2 diabetes | Superior HbA1c reduction | 40 weeks |
| SURMOUNT-OSA | Obstructive sleep apnoea with obesity | Large AHI reduction | 52 weeks |
Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
Does tirzepatide help PCOS?
The rationale is coherent — PCOS involves insulin resistance and GLP-1s improve it — but no GLP-1 is approved for PCOS and the dedicated trial evidence is thin.
Can a GLP-1 restore fertility in PCOS?
Weight loss can restore ovulation in people who were not ovulating. That is a benefit if you are trying to conceive and a contraception consideration if you are not.
Can I take tirzepatide while pregnant?
GLP-1s are not recommended in pregnancy, and labelling advises discontinuing before a planned pregnancy with a specified interval. Raise it with a prescriber at the start of treatment.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Tirzepatide for Type 2 DiabetesResearch
- Tirzepatide and Sleep Apnea: Evidence and FDA StatusJournal
- Compounded vs Brand Tirzepatide: Legal and Evidence DifferencesJournal
- Editorial StandardsCore & Trust
- Tirzepatide, Lean Mass and Muscle LossResearch
- Tirzepatide vs Semaglutide: What the Head-to-Head Trial ShowsJournal
- Tirzepatide and Type 2 Diabetes PreventionResearch
Related coverage
- Tirzepatide and Muscle Loss: What the Body-Composition Data Shows
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- GLP-1s and Vision: Two Different Issues That Get Conflated
- What a GLP-1 Actually Costs Over a Year, and Over Five
- GLP-1 Drug Interactions: The Three That Change Management
- Flat-Rate GLP-1 Pricing: What It Means and When It Saves Money
- Do Genetics Predict How Much You Lose on a GLP-1?
- Endoscopic Procedures to “Lock In” GLP-1 Weight Loss: Early Data, Big Caveats
GLP-1 Tirzepatide Rank. “Tirzepatide and PCOS: A Promising Signal With Thin Evidence.” S.J Partners LLC, 2026-08-03. https://glp1tirzepatiderank.com/tirzepatide-and-pcos-2026/
Quote the capture date beside a figure, not the date you read this page. Why.